Brief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
19/05/2026 13:52
May 19 (Reuters) - NKGen Biotech Inc NKGN.PK: NKGEN BIOTECH EXPANDS CLINICAL TRIAL SITE NETWORK FOR ALZHEIMER’S DISEASE PROGRAM ACROSS U.S. TO IMPROVE PATIENT ACCESS AND SUPPORT ENROLLMENT Source text: ID:nGNXzNXWr Further company coverage: NKGN.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program